Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields

World Journal of Surgical Oncology

Case Report

Vladimír Dbalý¹  Jan Klener¹  Jan Šroubek¹  František Tovaryš¹  Martin Syrůček²  Aaron Michael Rulseh³  Jiří Keller⁴  Josef Vymazal⁵ 

[1] Department of Neurosurgery, Na Homolce Hospital, Prague, Czech Republic;Department of Pathology, Na Homolce Hospital, Prague, Czech Republic;Department of Radiology, Na Homolce Hospital, Prague, Czech Republic;Department of Radiology, Na Homolce Hospital, Prague, Czech Republic;3rd Medical Faculty, Charles University in Prague, Prague, Czech Republic;Department of Radiology, Na Homolce Hospital, Prague, Czech Republic;Department of Neurology, 1st Medical Faculty, Charles University in Prague, Prague, Czech Republic;

关键词: Glioblastoma multiforme;    Recurrent glioblastoma multiforme;    Tumor-treating fields;    Long-term survival;   

DOI  :  10.1186/1477-7819-10-220

 received in 2012-02-22, accepted in 2012-09-13,  发布年份 2012

来源: Springer

【 摘 要 】

Glioblastoma multiforme (GBM) is the most common and malignant primary intracranial tumor, and has a median survival of only 10 to 14 months with only 3 to 5% of patients surviving more than three years. Recurrence (RGBM) is nearly universal, and further decreases the median survival to only five to seven months with optimal therapy. Tumor-treating fields (TTField) therapy is a novel treatment technique that has recently received CE and FDA approval for the treatment of RGBM, and is based on the principle that low intensity, intermediate frequency electric fields (100 to 300 kHz) may induce apoptosis in specific cell types. Our center was the first to apply TTField treatment to histologically proven GBM in a small pilot study of 20 individuals in 2004 and 2005, and four of those original 20 patients are still alive today. We report two cases of GBM and two cases of RGBM treated by TTField therapy, all in good health and no longer receiving any treatment more than seven years after initiating TTField therapy, with no clinical or radiological evidence of recurrence.

【 授权许可】

Unknown   
© Rulseh et al.; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.